Arformoterol Tartrate
Product Images NDC 0093-5955

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Arformoterol Tartrate (NDC 0093-5955). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (Image 1)

1 (Image 1)
FDA Label Image

1 (Image 10)

1 (Image 10)
This document appears to be a description of a medication called Arformoterol Tartrate Inhalation Solution. It comes in unit-dose ampules and is intended for oral inhalation only. The potency is expressed as arformoterol and is 15 mcg/2 mL. The medication should be refrigerated or stored at room temperature for up to 6 weeks. The document includes information about the packaging, with 60 x 2 mL sterile unit-dose ampules and 12 x 5 unit-dose ampules per pouch. The manufacturer appears to be Teva.*
FDA Label Image

1 (Image 11)

1 (Image 11)
This is a description of a medication, specifically Arformoterol Tartrate Inhalation Solution, available in a 15mcg*/2mL dose to be utilized via inhalation only. The medication comes in a pouch with 225 dose ampules that must be stored refrigerated or at room temperature (up to six weeks). The medication has to be protected against light and excessive storage temperatures and must be kept out of reach of children. The manufacturer is TelaRarmsceutias USA Inc in Farsoan.*
FDA Label Image

1 (Image 2)

1 (Image 2)
The text shows a graph with the title "Mean Change from Baseline FEV, (L)" and a horizontal axis indicating the hours post-dose with values ranging from 0 to 5. There are two lines on the graph: one representing the placebo group (with "ITT n=143" written alongside) and the other representing a treatment group that received 15 meg Arformoterol Tartrate BID (with "ITT n=141" written alongside). The baseline FEV for both groups is given in parentheses as 1.20 L for the placebo group and 1.15 L for the treatment group. The graph shows a gradual increase in FEV over time for both groups, with the treatment group showing a slightly higher increase compared to the placebo group.*
FDA Label Image

1 (Image 3)

1 (Image 3)
This appears to be a table or graph showing the mean change from a baseline FEV in liters after a certain number of hours post-dose for a placebo group and a group receiving 815 mcg of Arformoterol Tartrate twice a day, as indicated by the label at the bottom of the image. However, without more context it is difficult to provide a complete description.*
FDA Label Image

1 (Image 4)

1 (Image 4)
FDA Label Image

1 (Image 5)

1 (Image 5)
FDA Label Image

1 (Image 6)

1 (Image 6)
This text seems to be part of a larger document and does not provide sufficient information to generate a useful description.*
FDA Label Image

1 (Image 7)

1 (Image 7)
FDA Label Image

1 (Image 8)

1 (Image 8)
FDA Label Image

1 (Image 9)

1 (Image 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.